KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Operating Leases (2019 - 2025)

Inovio Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $7.3 million for Q3 2025.

  • For Q3 2025, Operating Leases fell 41.49% year-over-year to $7.3 million; the TTM value through Sep 2025 reached $7.3 million, down 41.49%, while the annual FY2024 figure was $9.4 million, 15.09% down from the prior year.
  • Operating Leases for Q3 2025 was $7.3 million at Inovio Pharmaceuticals, down from $8.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $19.3 million in Q2 2021 and bottomed at $7.3 million in Q3 2025.
  • The 5-year median for Operating Leases is $13.3 million (2023), against an average of $13.2 million.
  • The largest annual shift saw Operating Leases rose 0.0% in 2023 before it plummeted 41.49% in 2025.
  • A 5-year view of Operating Leases shows it stood at $15.5 million in 2021, then decreased by 18.14% to $12.7 million in 2022, then dropped by 12.83% to $11.0 million in 2023, then dropped by 15.09% to $9.4 million in 2024, then decreased by 22.27% to $7.3 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Operating Leases are $7.3 million (Q3 2025), $8.0 million (Q2 2025), and $8.7 million (Q1 2025).